Sökning: WFRF:(Kuusk Teele) >
2021 Updated Europe...
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma
-
- Bedke, Jens (författare)
- Department of Urology, University Hospital Tuebingen, Tuebingen, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany
-
- Albiges, Laurence (författare)
- Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France,Institut Gustave Roussy
-
- Capitanio, Umberto (författare)
- Department of Urology, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, IRCCS San Raffaele Hospital, Milan, Italy
-
visa fler...
-
- Giles, Rachel H. (författare)
- International Kidney Cancer Coalition (IKCC), Duivendrecht, Netherlands
-
- Hora, Milan (författare)
- Department of Urology, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic
-
- Lam, Thomas B. (författare)
- Academic Urology Unit, University of Aberdeen, Aberdeen, United Kingdom; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom
-
- Ljungberg, Börje, Professor, 1949- (författare)
- Umeå University,Umeå universitet,Urologi och andrologi
-
- Marconi, Lorenzo (författare)
- Department of Urology, Coimbra University Hospital, Coimbra, Portugal
-
- Klatte, Tobias (författare)
- Department of Urology, Charité – Universitätsmedizin Berlin, Berlin, Germany,Charité - University Medicine Berlin
-
- Volpe, Alessandro (författare)
- Department of Urology, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy
-
- Abu-Ghanem, Yasmin (författare)
- Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel
-
- Dabestani, Saeed (författare)
- Lund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,Urologi,Urological cancer, Malmö,Lund University Research Groups,Urology
-
- Fernández-Pello, Sergio (författare)
- Department of Urology, Cabueñes University Hospital, Gijón, Spain
-
- Hofmann, Fabian (författare)
- Umeå University,Umeå universitet,Urologi och andrologi,Sunderby Sjukhus, Luleå, Sweden
-
- Kuusk, Teele (författare)
- Department of Urology, Darent Valley Hospital, Dartford, United Kingdom; Gravesham NHS Trust, Dartford, United Kingdom
-
- Tahbaz, Rana (författare)
- Department of Urology, Charité – Universitätsmedizin Berlin, Berlin, Germany,Charité - University Medicine Berlin
-
- Powles, Thomas (författare)
- The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
-
- Bex, Axel (författare)
- The Royal Free London NHS Foundation Trust, London, United Kingdom; UCL Division of Surgery and Interventional Science, London, United Kingdom; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2022
- 2022
- Engelska.
-
Ingår i: European Urology. - : Elsevier. - 0302-2838 .- 1873-7560. ; 81:2, s. 134-137
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- Adjuvant treatment of nonmetastatic high-risk renal cell carcinoma is an unmet medical need. In the past, several tyrosine kinase inhibitor trials have failed to demonstrate an improvement of disease-free survival (DFS) in this setting. Only one trial (S-TRAC) provided evidence for improved DFS with sunitinib but without an overall survival (OS) signal. Keynote-564 is the first trial of an immune checkpoint inhibitor that significantly improved DFS with adjuvant pembrolizumab, a programmed death receptor-1 antibody, in clear cell renal cell carcinoma with a high risk of relapse. The intention-to-treat population, which included a group of patients after metastasectomy and no evidence of disease (M1 NED), had a significant DFS benefit. The OS data are not mature as yet. The Renal Cell Carcinoma Guideline Panel issues a weak recommendation for the adjuvant use of pembrolizumab for high-risk clear cell renal carcinoma, as defined by the trial until final OS data are available. However, the trial reilluminates the discussion on when and in whom metastasectomy should be performed. Here, caution is necessary not to perform metastasectomy in patients with poor prognostic features and rapid progressive disease, which must be excluded by a confirmatory scan of disease status prior to planned metastasectomy.Patient summary: New data from the adjuvant immune checkpoint inhibitor trial with pembrolizumab (a programmed death receptor-1 antibody) for the treatment of high-risk clear cell renal cell carcinoma (ccRCC) after surgery showed that the drug prolonged the period of being cancer free significantly, although whether it prolonged survival remained uncertain. Consequently, pembrolizumab is cautiously recommended as additional (ie, adjuvant) treatment in high-risk ccRCC after kidney cancer surgery.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Adjuvant
- Clear cell
- High risk
- Metastasectomy
- Pembrolizumab
- Renal cell carcinoma
- Tyrosine kinase inhibitor
- Adjuvant
- Clear cell
- High risk
- Metastasectomy
- Pembrolizumab
- Renal cell carcinoma
- Tyrosine kinase inhibitor
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bedke, Jens
-
Albiges, Laurenc ...
-
Capitanio, Umber ...
-
Giles, Rachel H.
-
Hora, Milan
-
Lam, Thomas B.
-
visa fler...
-
Ljungberg, Börje ...
-
Marconi, Lorenzo
-
Klatte, Tobias
-
Volpe, Alessandr ...
-
Abu-Ghanem, Yasm ...
-
Dabestani, Saeed
-
Fernández-Pello, ...
-
Hofmann, Fabian
-
Kuusk, Teele
-
Tahbaz, Rana
-
Powles, Thomas
-
Bex, Axel
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
European Urology
- Av lärosätet
-
Umeå universitet
-
Lunds universitet